1. Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia
- Author
-
Nuole Zhu, Miguel Santos-Santos, Ignacio Illán-Gala, Victor Montal, Teresa Estellés, Isabel Barroeta, Miren Altuna, Javier Arranz, Laia Muñoz, Olivia Belbin, Isabel Sala, Maria Belén Sánchez-Saudinós, Andrea Subirana, Laura Videla, Jordi Pegueroles, Rafael Blesa, Jordi Clarimón, Maria Carmona-Iragui, Juan Fortea, Alberto Lleó, and Daniel Alcolea
- Subjects
Glial fibrillary acidic protein ,Neurofilament ,Frontotemporal dementia ,Plasma biomarkers ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Background Astrocytes play an essential role in neuroinflammation and are involved in the pathogenesis of neurodenegerative diseases. Studies of glial fibrillary acidic protein (GFAP), an astrocytic damage marker, may help advance our understanding of different neurodegenerative diseases. In this study, we investigated the diagnostic performance of plasma GFAP (pGFAP), plasma neurofilament light chain (pNfL) and their combination for frontotemporal dementia (FTD) and Alzheimer’s disease (AD) and their clinical utility in predicting disease progression. Methods pGFAP and pNfL concentrations were measured in 72 FTD, 56 AD and 83 cognitively normal (CN) participants using the Single Molecule Array technology. Of the 211 participants, 199 underwent cerebrospinal (CSF) analysis and 122 had magnetic resonance imaging. We compared cross-sectional biomarker levels between groups, studied their diagnostic performance and assessed correlation between CSF biomarkers, cognitive performance and cortical thickness. The prognostic performance was investigated, analyzing cognitive decline through group comparisons by tertile. Results Unlike pNfL, which was increased similarly in both clinical groups, pGFAP was increased in FTD but lower than in AD (all P
- Published
- 2021
- Full Text
- View/download PDF